China Resources Pharmaceutical Group Limited (01093.HK): The long-acting injection of octreotide (SYHX2008) has been approved for clinical trials in the United States.

Wisdom Financial APP News, Shiyao Group (01093.HK) announced that the long-acting injection of Aeluroide peptide developed by the Group (SYHX2008) has been approved by the Food and Drug Administration (FDA) of the United States and can conduct clinical trials in the United States.